Bringing New Hope
Chronic Pain Affects 100 Million Americans
At EicOsis, our mission is to develop new effective and safe oral medicines to help people suffering from pain and inflammation. We are committed to improving the lives of those suffering from pain, helping them feel themselves again. Contact us.
Dr. Hammock is a Distinguished Professor at the University of California, Davis. Dr. Hammock is an elected member of the National Academy of Sciences, US (1999). He has over 30 years of extensive experience in the field of eicosanoids that yielded over 1000 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors.
Dr. McReynolds is an experienced sEHI researcher, and co-founder of EicOsis. She has previously managed preclinical efforts through Phase II clinical trials for start-up and semi-virtual biotech companies.
Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 4 biotech companies.
Dr. Cortés-Puch is a critical care medicine physician and researcher with expertise in study design, intensive care medicine and translational medicine. She spent 5 years conducting translational research at the National Institutes of Health and is currently a scientist at UC Davis Division of Pulmonary and Critical Care Medicine.
Robert Gregoire is an experienced CEO, founder, and board member with over 25 years of organizational leadership in diversified industries. He specializes in developing strategies, engaging teams, and implementing change in organizations experiencing life-cycle transitions, emphasizing capacity, growth, and long-term sustainability. Concurrently, he serves as the CEO of an organization that provides fractional business teams.
Dr. Hwang is a synthetic chemist with expertise in the design, synthesis, and characterization of small molecules in medicinal chemistry. He leads the development of highly potent inhibitors of epoxide hydrolase and cyclooxygenase enzymes.
Dr. Wagner is a pharmacologist with extensive experience in investigating the role of lipid mediators in neurobiology. She has expertise with animal behavior and in vivo experimentation and leads the preclinical research of the role of sEH inhibition in pain.
Dr. Yang is an analytical chemist with expertise in the DMPK and analyses of small molecules in medicinal chemistry. He leads the research on DMPK of highly potent inhibitors of epoxide hydrolase and biomarker assessment.
